About the Marlene and Stewart Greenebaum Comprehensive Cancer Center

UMGCCCThe University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center is one of the top cancer treatment and research centers in the country. In 2016, the National Cancer Institute elevated UMGCCC to its designation as a comprehensive cancer center — one of only 50 in the nation. As part of the University of Maryland Medical Center, we offer innovative approaches to diagnosing and treating all types of cancer, conduct cutting-edge research to bring the latest advances in cancer treatment directly to our patients, and provide cancer screening and patient education services.



Our National Profile

In 2016, UMGCCC became a National Cancer Institute (NCI)-Designated Comprehensive Cancer Center, a distinction shared by some 50 centers across the US.

UMGCCC is ranked among the top 50 cancer programs in the country, according to U.S. News & World Report’s Best Hospitals list.

Cancer research funding at UMGCCC has grown dramatically since 2002 — from $19.4 million to $90.8 million — and continues to drive scientific discovery by our cancer experts, all of whom are faculty of the UM School of Medicine.

UMGCCC is a leader in addressing cancer disparities, with research focused on improving access to care and treatment outcomes for minorities, who represent 37 percent of the patients in our clinical trials, compared to 16 percent nationally.

The Maryland Proton Treatment Center, a next-generation radiation treatment facility, began treating patients in 2016 in the University of Maryland BioPark. Because of its precision, proton therapy is thought to be beneficial for some patients with tumors near vital organs, as well as for pediatric patients.

UMGCCC is a national leader in developing new immunotherapy approaches that train a patient’s own immune system to fight cancer. More than two dozen clinical trials utilize immunotherapy. These trials are supported by UMGCCC’s new Fannie Angelos GMP (Good Manufacturing Practice) Lab which permits cancer center investigators to genetically engineer patients’ T cells to recognize and attack their cancers.

The UMGCCC was the first cancer center in the Baltimore/ Washington area to offer CAR-T cell therapy for B cell lymphomas. A number of clinical trials with this innovative therapy are currently underway for lymphoma and leukemia.

Dr. Cedric Yu and Dr. William Regine invented and developed the GammaPod, a stereotactic radiotherapy system uniquely dedicated to treating early-stage breast tumors. Now FDA cleared, the device is undergoing clinical trials which may simplify the treatment of early breast cancers with fewer side effects.

Galeterone, a drug invented at UMGCCC by investigators Angela Brodie and Vincent Njar, has shown significant activity against advanced prostate cancer. More recent studies are promising in laboratory models of pancreatic cancer. A clinical trial for this difficult disease starts soon.

Dr. Graeme Woodworth received FDA clearance to become the first in the US to open the blood-brain barrier, which protects the brain from toxins but makes it difficult to treat brain cancer with chemotherapy. By using focused ultrasound and microbubbles, UM can disrupt the barrier and inject an agent directly into a brain tumor.

To read more about the Marlene and Stewart Greenebaum Comprehensive Cancer Center, visit www.umms.org/umgccc.


Meet our Volunteer Leadership

Greenebaum Comprehensive Cancer Center's Board of Advisors

Mr. Barry Stoler

Mrs. Marie G. Bowers

Mr. Jay C. Feinglass

Mr. S. Robert Ginsberg

Mrs. Sonya Z. Goodman

Mr. Michael I. Greenebaum

Mr. Richard Hoffman, Esq.

Mr. Erik D. Johnson

Mrs. Donna M. Maykrantz

Mr. Lawrence F. Maykrantz

Ms. Susan Mertes

Mr. Jonathan P. Myers

Ms. Ricka E. Neuman, CPA

Mr. Ian H. Neuman

Ms. Tswana Sewell

Mr. Alex Smith

Mr. Stuart Weitzman


Emeritus Members

Mrs. Roslyn Stoler

Ms. Paula Rome

Mrs. Edith Wolpoff-Davis